These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23891090)

  • 1. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells.
    Saki M; Toulany M; Rodemann HP
    Radiother Oncol; 2013 Sep; 108(3):473-8. PubMed ID: 23891090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
    Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
    Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
    Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
    Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
    Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
    Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N
    Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
    Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
    Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway.
    Toulany M; Dittmann K; Krüger M; Baumann M; Rodemann HP
    Radiother Oncol; 2005 Aug; 76(2):143-50. PubMed ID: 16024124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
    Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
    Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature.
    Rabinowits G; Haddad RI
    Oral Oncol; 2012 Nov; 48(11):1085-9. PubMed ID: 22840785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.
    Hobor S; Van Emburgh BO; Crowley E; Misale S; Di Nicolantonio F; Bardelli A
    Clin Cancer Res; 2014 Dec; 20(24):6429-38. PubMed ID: 24916700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs.
    Minjgee M; Toulany M; Kehlbach R; Giehl K; Rodemann HP
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1506-14. PubMed ID: 21985943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity.
    Toulany M; Baumann M; Rodemann HP
    Mol Cancer Res; 2007 Aug; 5(8):863-72. PubMed ID: 17699110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
    van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
    Eke I; Cordes N
    Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.